of BC patients. In addition, BCG induced expression of key immunomodulatory molecules in BC cells and within the EVs. This up-regulated expression of immuno-molecules in response to BCG supports the hypothesis that EVs have a role in activating the immune system during BCG immunotherapy. The immunologically active EVs detected in patients' urine can be further explored as predictive biomarkers.
INTRODUCTION AND OBJECTIVES: Cancer field effect describes the predisposition of a field of tissue with histological anomalies or molecular alterations to a high incidence of tumor initiation and has been proposed to explain bladder cancer's (BC's) multifocal and recurrence nature, yet its mechanisms remain unknown. Extracellular vesicles (EVs) are small, membrane-bound vesicles with functions in cell-cell communication. We hypothesize that EVs derived from BC cells transfer bioactive cargo to reprogram recipient cells in the field and induce malignant transformation.
METHODS: EVs from TCC-SUP, a BC line, were collected and purified. SV-HUC cells, a non-malignant immortalized urothelial line, were used as recipients. Tumorigenicity was determined by an in vitro anchorage-independent colony formation assay and an in vivo xenograft mouse model. Hallmarks of cancer such as loss of contact inhibition, genome instability, and invasion were studied. Molecular alterations in EV-transformed cells were assayed by qPCR and Western blot. Pro-inflammatory cytokines were compared by multiplex ELISA assays.
RESULTS: Bladder cancer EVs induced malignant transformation of SV-HUC cells in vitro and in vivo. Molecular profiling revealed abnormal levels of endoplasmic reticulum (ER) stress sensors/ effectors and pro-inflammatory cytokines in transformed cells. Moreover, the expression of ER chaperone protein Grp78 and two ER resident sensors, PERK and IRE1, was induced. Pro-apoptotic ER stress effector CHOP was absent, suggesting cancer EVs promote tumorigenesis by activating tumor-promoting signals while inhibiting pro-apoptotic signals.
CONCLUSIONS: Our data support a novel mechanism whereby cancer EVs and their cargo molecules play key roles in the malignant field of BC. Our study reveals that cancer EVs promote malignant transformation of predisposed cells by inhibiting pro-apoptotic signals and activating tumor-promoting ER stress induced unfolded protein response and inflammation. This study provides insight into mechanism of BC's field effect and suggests EV as potential markers of disease recurrence and progression currently intense interest in the reactivation of placental and developmental genes in cancer, given the inherently "oncogenic" tissue invasion and immune evasion properties of the placenta. Although transposon ability was lost 120 million years ago, PEG10 retains the ability to self-cleave, in an apparently homologous manner, to HIV. We have recently identified that PEG10 promotes cell cycle progression in the context of TP53 and RB1 loss in neuroendocrine prostate cancer. Based on the evidence that TP53 mutations and RB1 inactivation are more prevalent in muscle invasive bladder cancer (MIBC), we hypothesized that PEG10 may be concerned to the poor prognosis of MIBC. To test this hypothesis, we characterized PEG10 function in bladder cancer and evaluated if PEG10 can be a novel therapeutic target for bladder cancer. We also investigated whether Ritonavir, which is an antiretroviral medication used to treat HIV/AIDS, suppresses the expression of PEG10 and induced growth suppression in T24 cells.
METHODS: PEG10 gene expression of tumor samples was analyzed using the cancer genome atlas (TCGA) cohort. The PEG10 expression in several bladder cancer cell lines was assessed by Western blot analysis and quantitative reverse transcription-PCR (qRT-PCR). Silencing of PEG10 in vitro was achieved using siRNA. The in vivo effect of PEG10 antisense oligonucleotide (ASO) treatment was assessed in the T24 orthotopic bladder cancer model. RESULTS: Higher mRNA level of PEG10 was significantly associated with poorer disease-free survival after cystectomy in 131 patients in the TCGA, Nature 2014 cohort. We examined PEG10 expression in a panel of 12 bladder cancer cell lines by Western blot. UM-UC14 showed the highest PEG10 expression, and T24 showed higher PEG10 expression than the other bladder cancer cell lines. Similar results were confirmed by qRT-PCR. PEG10 transient knockdown using two independent siRNAs resulted in significant growth suppression in UM-UC14 (RB1inactivatedTP53mut) and T24 (RB1wtTP53mut) cells. PEG10 knockdown induced higher expression of key cell cycle dependent kinase inhibitors p21 and p27 than observed in the control cells. Conversely, forced PEG10 RF1b/2 isoform over-expression induced cell growth in UC14 and T24 cells. Furthermore, UM-UC14 cell invasion was significantly decreased with PEG10 transient knockdown. Using the BrdU incorporation assay after cell cycle synchronization by doublethymidine block, we found that PEG10 drives cell cycle progression from G0/G1. In the orthotopic bladder cancer model, systemic PEG10-ASO administration to athymic nude mice delayed tumor progression in T24 cells. Surprisingly, Ritonavir suppressed the expression of PEG10 and induced growth suppression in T24 cells.
CONCLUSIONS: We have demonstrated that PEG10 promotes bladder cancer progression. Inhibition of PEG10 may be a novel treatment strategy for a subset of bladder cancer. 
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INTRODUCTION AND OBJECTIVES:
In studies on human bladder cancer cell lines, BCG induced the expression of GST theta 2 (GSTT2) a member of the Glutathione-S-transferase family. The objective of this study was to investigate the cellular function of GSTT2 and its impact on the response to BCG therapy in NMIBC patients.
METHODS: GSTT2B (pseudogene) deletion decreases GSTT2 expression. PCR was performed to identify GSTT2B presence or absence in human bladder cancer and macrophage cell lines, and in patients (n¼139) and controls (n¼150) (IRB approval, NHG DSRB: 2012/ 00475) GSTT2 silencing (siRNA) and overexpression (plasmid carrying GSTT2) were performed on selected cell lines. Reactive oxygen species (ROS); BCG induced cytotoxicity and intracellular BCG survival were analyzed. Patient demographic, initial disease characteristics (based on EORTC scoring system) and therapy outcomes were evaluated with Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e853 respect to the GSTT2B genotypes. The impact of BCG instillation (numbers) on recurrence was analyzed in a subset of patients for whom complete 10y follow-up data was available. Analysis was performed using SPSS 23.0 and p<0.05 was taken to be significant. RESULTS: GSTT2 was silenced in MGH cells (GSTT2B homozygous full length (GSTT2B fl/fl )) and overexpressed in UMUC3 and U937 cells (GSTT2B homozygous deleted (GSTT2B del/del )). A 2h exposure to BCG resulted in decreased ROS in GSTT2 silenced cells (p<0.05) and increased ROS in GSTT2 overexpressing cells (p<0.05). There was no difference in cellular cytotoxicity to BCG with respect to GSTT2 expression. However, intracellular BCG survival increased at 2 hours when GSTT2 was silenced (p<0.05) and decreased when GSTT2 was overexpressed (p<0.05). There was no significant difference between these groups at 24h. The majority of patients with complete 10y follow-up data, completed a 6+3 BCG schedule (n¼63) and n¼22 had less than 8 instillations. Patients with GSTT2B del/del genotype (n¼6) who received 8 or less BCG instillations, were recurrence free (Likelihood ratio ¼ 0.040, p¼0.054). In the group that received at least 9 instillations of BCG, the GSTT2B del/del was associated with earlier recurrence.
CONCLUSIONS: GSTT2 expression decreases cellular ROS and BCG survival. GSTT2B del/del was associated with lower likelihood of recurrence for patients who received 8 or less BCG instillations. In contrast patients with GSTT2B del/del who received 9 or more instillations of BCG had earlier recurrences. Hence GSTT2B del/del could be used as a marker for patients who will do well with less BCG therapy. 
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INTRODUCTION AND OBJECTIVES:
Though BCG immunotherapy reduces the incidence of recurrence and progression there are still patients who fail therapy. This could be due to an inability to generate activated antigen specific T cells. CLTA4 modulates the activation of T cells. The objective of this study was to determine if CTLA4 (Rs733618, Rs4553808, Rs5742909, Rs231775, Rs3087243, Rs565213 and Rs960792) Single Nucleotide Polymorphisms (SNPs) modulate the incidence and outcomes to BCG immunotherapy.
METHODS: DNA was obtained from bladder cancer patients attending the National University Hospital (n¼139) and healthy controls (n¼150) (IRB approval, NHG DSRB: 2012/00475). SNPs were evaluated using PCR followed by high resolution melt analysis. Patients received either standard or low dose BCG or low dose BCG+IFNa. The median length of follow up was 97 months (range 2.4 -205.2 months). Time to events are presented as meanAEstandard error (95% confidence intervals) in months. Multivariate Cox & Logistic regressions were performed to assess the impact of the genotypes, treatment, tumor stage, grade, age, smoking history and gender on time to clinical outcomes (recurrence, progression and death) and their incidences, respectively. Analysis was performed using SPSS 23.0 and p<0.05 was taken to be significant.
RESULTS: There was no statistical difference between the 3 treatment groups, therefore standard BCG and low BCG (B) were combined and compared to low dose BCG+IFNa (BI). BI therapy significantly improved outcomes for patients with Rs733618CC (B vs BI, 13 patients, p¼0.019), Rs7565213GG (B vs BI, 52 patients, p¼0.015) and Rs960792TT (B vs BI, 52 patients, p¼0.04) in terms of time to recurrence and with Rs231775GG (B vs BI, 41 patients, p¼0.039) and Rs7565213GG (B vs BI, 53 patients, p¼0.032) in terms of time to progression. Patients with Rs960792CC had earlier recurrences with BI therapy (B:10 vs BI:11 patients, p¼0.08). In subjects with the combination of genotypes: Rs3087243GG, Rs7565213GG and Rs960792TT (B:22 vs BI:18 patients), treatment with BI resulted in increased recurrence free survival time ) months vs 154. ) months, p¼0.025) and increased time to cancer specific death ) months vs 150. 
INTRODUCTION AND OBJECTIVES: Intravesical BCG
Immunotherapy is the standard of care in treating non-muscle invasive bladder cancer, yet its mechanism of action remains elusive. While prior research has indirectly demonstrated the importance of T cells and shown a rise in CD4+ T cells in bladder tissue after BCG, the role of T cells in BCG anti-tumor activity has not been characterized. We investigated T cell recruitment and differentiation after BCG in an immune competent, clinically relevant rodent model of bladder cancer.
METHODS: Fischer 344 rats aged 7 weeks received 1.5mg/kg N-Nitroso-N-methylurea (MNU) every other week for 6 weeks (4 doses). Dysplasia begins by week 8 and by week 16 the majority of rats have a NMIBC phenotype. Beginning week 8 following the first MNU dose, rats were intravesically administered 0.3ml of BCG (Ticeâ), cisplatin (1mg/ ml), Mitomycin C (2mg/ml), MMC+ BCG, or saline (n¼10 for all groups) weekly for 6 total doses. Animals were sacrificed at week 16, and bladders were processed for histopathology and digested into single cell suspensions for flow cytometry. Whole transcriptome expression profiling was then performed on sorted CD4 and CD8 cells of post-BCG tumors vs untreated tumors to assess T cell differentiation after BCG.
RESULTS: Our data demonstrate that cancer progression in the MNU rat model of bladder cancer is characterized by a decline in the CD8/FoxP3 ratio, consistent with decreased adaptive immunity. By contrast, treatment with intravesical BCG leads to a large, transient rise in the CD4+ T cell population in the urothelium, and is both more effective and immunogenic compared to intravesical chemotherapy. Interestingly, whole transcriptome expression profiling of post-treatment intravesical CD4+ and CD8+ T cells revealed minimal differences in gene expression after BCG treatment.
CONCLUSIONS: Together, our results suggest that while BCG induces T cell recruitment to the bladder, the T cell phenotype does not markedly change, implying that combining T cell activating agents with BCG might improve clinical activity. 197, No. 4S, Supplement, Sunday, May 14, 2017 
